Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07538583 · ClinicalTrials.gov registry record · Phase 2
Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
A Phase 2 study, sponsored by Quoin Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT07538583: Recruiting Phase 2 study, sponsored by Quoin Pharmaceuticals.
NCT07538583 is a Phase 2 study that is actively recruiting participants, run by Quoin Pharmaceuticals. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07538583, a Phase 2 study, is actively recruiting participants, sponsored by Quoin Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.
Primary Outcome
The IGA (Investigator Global Assessment) is a 5-point scale used to assess the overall severity of a Subject's NS condition.
Interventions
- DRUG QRX003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-03-19 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
What NCT07538583 shows while recruiting
NCT07538583 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which QRX003 is the first listed.
NCT07538583 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07538583 about?
NCT07538583 is a clinical study titled "Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome". This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body S...
What is the current status of trial NCT07538583?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2026-03-19. Estimated completion is 2027-03-31.
What interventions are being tested in trial NCT07538583?
The interventions under investigation include: QRX003 (DRUG).
Who is sponsoring clinical trial NCT07538583?
This trial is sponsored by Quoin Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07538583's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI